With sales declining for hepatitis C fixed-dose combo Viekira Pak, AbbVie Inc. wants to convince investors that its cancer portfolio and pipeline – led by hematology drugs Imbruvica and Venclexta – offer a pathway to sales growth that will enable the pharma to keep diversifying from top-seller Humira.
AbbVie has been criticized as a one-product shop since it was spun out of parent Abbott in 2013, and much...







